Q-omics provides the consensus-scored RPS6KA2-AS1 profile across patient tissues and cancer cell-line models. RPS6KA2-AS1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPS6KA2-AS1 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, RPS6KA2-AS1 RNA expression shows 9,811 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight HNSC, KIRC, and LAML as cancer lineages where RPS6KA2-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS6KA2-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS6KA2-AS1 survival associations across molecular data types. RPS6KA2-AS1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS6KA2-AS1 RNA expression–survival associations across cancer types. High RPS6KA2-AS1 expression shows unfavorable associations in UVM, LIHC, READ and ACC, but favorable associations in HNSC and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for RPS6KA2-AS1 RNA expression.
This table summarizes RPS6KA2-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS6KA2-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS6KA2-AS1 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, STAD, BLCA and CHOL. The KIRC box plot shows higher RPS6KA2-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.111, t-test p < 0.001).
This table shows molecular features associated with RPS6KA2-AS1 in patient tissues and cancer cell lines. In patient samples, RPS6KA2-AS1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
